• Improving Patient 
    Outcomes in
    Solid Tumor
    Cancer Treatment

    BIO300
    A New Class of Cancer Drug

  •  

    COVID-19

     

    BIO300
    Preventing long term lung damage caused by inflammation

  • Keeping America Safe

    BIO300
    Protecting Civilians, First Responders and Our Military
    from Nuclear Accidents and Terrorism

Humanetics News

05.24.2023

BIO 300 Enhances Efficacy of Radiotherapy Against Lung Tumors in a Nonclinical Model
Read More

02.15.2023

Humanetics  Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Trial in COVID-19 Patients
Read More

02.07.2023

BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
Read More

12.16.2022

Humanetics Corporation Presents at the MedInvest Oncology Investor Conference
Read More

11.15.2022

Humanetics Corporation Publishes Results of Phase 1 Trial of BIO 300 Oral Powder in Healthy Volunteers
Read More

10.25.2022

Humanetics Corporation Presents at the 2022 Annual Radiation Research Society Meeting
Read More

10.05.2022

FDA Clears BIO 300 for Studies in Second Oncology Indication
Read More

09.22.2022

Thomas F. Jasper Joins Board at Humanetics
Read More

08.09.2022

Jake R. Nunn Joins Board at Humanetics
Read More

07.27.2022

BIO 300 Pharmacokinetics Data Published
Read More

06.21.2022

US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure
Read More

05.18.2022

Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites
Read More

04.26.2022

Humanetics Corporation Publishes New Data Comparing BIO 300 with Neulasta
Read More

04.13.2022

Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors
Read More